| Catalog | Description | Size | Price (USD) | Qty |
|---|---|---|---|---|
| GBM-4661-20MG | Repaglinide | 20mg | $63.00 | |
| GBM-4661-100MG | Repaglinide | 100mg | $200.00 |
| Bioassays Specification | |
| Bio-Activity | Kir6 blocker |
| Chemical Name | 2-Ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid |
| Function / Pharmacology | Blocker of the ATP-sensitive potassium channel Kir6 with hypoglycemic activity.1 Clinically useful antidiabetic agent. It displays 30-fold selectivity for pancreatic Kir6.2/SUR1 over cardiac Kir6.1/SUR2B and Kir6/SUR2A channels.2 Repaglinide displayed neuroprotective effects in Huntington disease3, Parkinson’s disease4, and ALS5 via blockade of the DREAM-ATF6 interaction. |
| CAS# | 135062-02-1 |
| MW | 452.6 |
| Molecular Formula | C27H36N2O4 |
| Solubility | Soluble in DMSO (up to 25 mg/ml) |
| Supplied | powder |
| Storage as supplied | -20°C |
| Ship temp | Ambient |
| References | 1) Mark and Grell (1997), Hypoglycaemic effects of the novel antidiabetic agent repaglinide in rats and dogs; Br. J. Pharmacol. 121 1597 2) Stephan et al. (2006), Selectivity of repaglinide and glibenclamide for the pancreatic over the cardiovascular K(ATP) channels; Diabetologia 49 2039 3) Naranjo et al. (2016), Activating transcription factor 6 Activating transcription factor 6 derepression mediates neuroprotection in Huntington disease; J. Clin. Invest. 126 627 4) Motawi et al. (2023), Repaglinide Elicits a Neuroprotective Effect in Rotenone-Induced Parkin’s Disease in Rats: Emphasis on Targeting the DREAM-ER Stress BiP/ATF6/CHOP Trajectory and Activation of Mitophagy; ACS Chem. Neurosci. 14 180 5) Gonzalo-Gobernado et al. (2023), Repaglinide Induces ATF6 Processing and Neuroprotection in Transgenic SOD1G93A Mice; Int. J. Mol. Sci. 24 15783 |
| Protein Specification | |
| Purity | >98% |
| Bioassays Specification | |
| Bio-Activity | Kir6 blocker |
| Chemical Name | 2-Ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid |
| Function / Pharmacology | Blocker of the ATP-sensitive potassium channel Kir6 with hypoglycemic activity.1 Clinically useful antidiabetic agent. It displays 30-fold selectivity for pancreatic Kir6.2/SUR1 over cardiac Kir6.1/SUR2B and Kir6/SUR2A channels.2 Repaglinide displayed neuroprotective effects in Huntington disease3, Parkinson’s disease4, and ALS5 via blockade of the DREAM-ATF6 interaction. |
| CAS# | 135062-02-1 |
| MW | 452.6 |
| Molecular Formula | C27H36N2O4 |
| Solubility | Soluble in DMSO (up to 25 mg/ml) |
| Supplied | powder |
| Storage as supplied | -20°C |
| Ship temp | Ambient |
| References | 1) Mark and Grell (1997), Hypoglycaemic effects of the novel antidiabetic agent repaglinide in rats and dogs; Br. J. Pharmacol. 121 1597 2) Stephan et al. (2006), Selectivity of repaglinide and glibenclamide for the pancreatic over the cardiovascular K(ATP) channels; Diabetologia 49 2039 3) Naranjo et al. (2016), Activating transcription factor 6 Activating transcription factor 6 derepression mediates neuroprotection in Huntington disease; J. Clin. Invest. 126 627 4) Motawi et al. (2023), Repaglinide Elicits a Neuroprotective Effect in Rotenone-Induced Parkin’s Disease in Rats: Emphasis on Targeting the DREAM-ER Stress BiP/ATF6/CHOP Trajectory and Activation of Mitophagy; ACS Chem. Neurosci. 14 180 5) Gonzalo-Gobernado et al. (2023), Repaglinide Induces ATF6 Processing and Neuroprotection in Transgenic SOD1G93A Mice; Int. J. Mol. Sci. 24 15783 |
| Protein Specification | |
| Purity | >98% |
